Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 
Wednesday, 31 July 2019

Appendix 4C

  CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow Report for the period 01 April to 30 June 2019.   Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD today announced that non-executive Director, Willem Blijdorp has replaced Managing Director and Chief Executive Officer, Dr Philippe Wolgen as a member of the Audit & Risk Committee. […] Download PDF

Download PDF
 
 
Thursday, 11 July 2019

CLINUVEL Newsletter – July 2019

  In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for SCENESSE® (afamelanotide 16mg) by three months […] Download PDF

Download PDF
 
 

   21 June 2019      Download PDF

Download PDF
 
 

CLINUVEL INCLUDED IN S&P/ASX 200 INDEX 14 June 2019 Download PDF    

Download PDF
 
 

6 June 2019   Download PDF

Download PDF
 
 

Melbourne, Australia 5 June 2019 Download PDF

Download PDF
 
 

Melbourne, Australia 3 June 2019 Download PDF The FDA sets new goal date of 6 October 2019 to complete review and issue risk-benefit decision CLINUVEL PHARMACEUTICALS LTD today published that the US Food and Drug Administration (FDA) Division of Dermatology and Dental Products (DDDP) has set a new Prescription Drug User Fee Act (PDUFA) goal […]

Download PDF
 
 

Melbourne, Australia 3 June 2019 Download PDF The FDA sets new goal date of 6 October 2019 to complete review and issue risk-benefit decision   Executive summary New PDUFA goal date set for 6 October 2019 New timeline to communicate labelling changes and post-marketing commitments by 6 September 2019 Scientific exchange between FDA and CLINUVEL […]

Download PDF
 
 

15 May 2019   Download PDF

Download PDF
 
 
Wednesday, 08 May 2019

Becoming a substantial holder

08 May 2019   Download PDF

Download PDF
 
 
Thursday, 02 May 2019

CLINUVEL Newsletter

02 May 2019 Download PDF   Dear patients, shareholders, friends, In this Communiqué we concentrate on CLINUVEL’s programs and US market access for SCENESSE®. As the European season unfolds, we report on the back of quarterly financials (released 30 April) which are on track against our own projections. Importantly, our commercial teams and finance staff […]

Download PDF
 
 
Tuesday, 30 April 2019

Appendix 4C

Melbourne, Australia, 30 April 2019 Download PDF   CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow Report for the period 01 January to 31 March 2019. All figures are rounded and […]

Download PDF
 
 
Wednesday, 24 April 2019

Chair Letter to Shareholders

24 April 2019   Download PDF   Dear All, On a continent where very few biotechnology and pharmaceutical companies have ever succeeded in taking a first-in-class and first-in-line therapy from concept to commercialisation, CLINUVEL has all the makings of becoming a lasting success story in Australian life sciences. It will become a Company serving many […]

Download PDF
 
 

04 April 2019   Download PDF to view presentation

Download PDF
 
Thursday, 11 July 2019

CLINUVEL Newsletter - July 2019

  In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for …

Download PDF
 
Thursday, 02 May 2019

CLINUVEL Newsletter

02 May 2019  Dear patients, shareholders, friends,In this Communiqué we concentrate on CLINUVEL’s programs and US market access for SCENESSE®.As the European season unfolds, we report on the back of quarterly financials (released 30 April) …

Download PDF
 
Wednesday, 24 April 2019

Chair Letter to Shareholders

24 April 2019   Dear All,On a continent where very few biotechnology and pharmaceutical companies have ever succeeded in taking a first-in-class and first-in-line therapy from concept to commercialisation, CLINUVEL has all the makings of becoming …

Download PDF
 
Wednesday, 20 March 2019

CLINUVEL Newsletter – March 2019

20 March 2019  Dear patients, shareholders, friends,In the third Communiqué we are reviewing our EU operations, the impact of Brexit and looking at the year ahead. FDA REVIEWAt the time of print CLINUVEL will find itself …

Download PDF
 
Tuesday, 12 February 2019

CLINUVEL Vitiligo Communiqué II

12 February 2019   In the second Communiqué we look closer at the role of narrowband UVB (NB-UVB) as the only standard of care at present in vitiligo, both the segmental and generalised form of the disease. …

Download PDF
 
Tuesday, 15 January 2019

CLINUVEL Newsletter - January 2019

15 January 2019 Dear patients, shareholders, friends,I wish you all a year in good physical and spiritual health, and a year in which we anticipate further progress of SCENESSE ® (afamelanotide 16mg)1 and CLINUVEL’s other products …

Download PDF
 
Thursday, 10 January 2019

US FDA sets PDUFA date for SCENESSE®

Melbourne, Australia 10 January 2019 Priority Review granted for innovative drug, PDUFA date 8 July 2019  Executive summary New Drug Application submitted in accordance with section 505(b) of the Federal Food, Drug, and Cosmetic Act, filed in …

Download PDF
 
Wednesday, 19 December 2018

CLINUVEL Vitiligo Communiqué

19 December 2018 As a depigmentation disorder (hypomelanosis), vitiligo is the most well-known of all leucodermatoses (“white skin”) whereby other variants of loss of skin pigmentation – temporary or permanent - are described as albinism, piebaldism, …

Download PDF
 
Monday, 17 December 2018

CLINUVEL Newsletter - December 2018

17 December 2018 As the year draws to a close we look back at a hectic, yet successful, 12 months. In CLINUVEL’s marathon, the past year looked like a series of endless sprints to accomplish all we had …

Download PDF
 
Monday, 05 November 2018

CLINUVEL Newsletter - November 2018

05 November 2018 The most recent quarterly financial results (1 July-30 September 2018) confirm the steady growth in clinical demand for SCENESSE® (afamelanotide 16mg) in erythropoietic protoporphyria (EPP), a rare genetic metabolic disorder.1 EPP is classified …

Download PDF